Genomtec S.A., a biotech company that develops solutions for molecular diagnostics, including the innovative Genomtec ID diagnostic system, put all 730 thousand shares of the J-series offered at a maximum price of 11 PLN per share as part of the first public offering. It is noted that investors have noticed a tremendous potential and innovation […]
Read the full articleGenomtec S.A. launched a public offering of up to 730,000 J-series shares. The maximum price was set at PLN 11 per share. All funds from the issue of shares (7.5 PLN mln after costs of conducting) will be used in preparation for the industrialization and mass production of the Genomtec ID platform. Including received grants, […]
Read the full articleBioceltix S.A. has reached another milestone – approval for the production of a veterinary medicinal product for cell therapy – according to decision of the Main Pharmaceutical Inspectorate. Bioceltix, as one of the few companies in the world, received such consent, and it confirms that the direction of the Company’s development chosen by the Management […]
Read the full article
